Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data
Guofeng Chen(302 Military Hospital of China), George Lau(Humanity & Health), Jidong Jia(National Clinical Research Center for Digestive Diseases), Hong Ren(Xuzhou Medical College), Jiuping Wang(Air Force Medical University), Qingchun Fu(Nanjing General Hospital of Nanjing Military Command), Zhansheng Jia(Tang Du Hospital), Xiao-Xia Niu(Chinese PLA General Hospital), Jinlin Hou(Southern Medical University), Dong Ji(Humanity & Health), Vanessa Wu(Humanity & Health), Xiaoguang Dou(China Medical University), April Wong(Humanity & Health), Wenhong Zhang(Fudan University), Qing Xie(Ruijin Hospital), Jialiang Liu(National Clinical Research Center for Digestive Diseases), Ying Han(Beijing University of Chemical Technology), Hui Zhuang(Institute of Crop Sciences), Yudong Wang(Shanxi University), Jing Chen(Chinese Academy of Sciences), Cheng Wang(Gansu Provincial Maternal and Child Health Hospital), Lai Wei(Tongji University), Ning Du(Shandong University), Jun Cheng(Central South University), Bing Li(302 Military Hospital of China), Yuexin Zhang(University of Houston), Fan Li(Universität Hamburg), Guiqiang Wang(Qinghai University), Lungen Lu(Shanghai Jiao Tong University), Jian‐Gao Fan(XinHua Hospital), Zhongping Duan(Beijing YouAn Hospital), Xingxiang Yang(Qingdao University), Xiaojin Wang(Shanghai Jiao Tong University), Qing Shao(302 Military Hospital of China), Jia Shang(European Foundation for the Study of Chronic Liver Failure)
Cited by 44
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
|New England Journal of Medicine|2005|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789